USE OF cADPR OR NAADP ANTAGONISTS

Abstract

When using a pharmaceutical composition for preventing or treating malignant hyperthermia, containing NAADP antagonists, of the present invention, malignant hyperthermia can be effectively prevented or treated through the inhibition of an oxygen consumption rate abnormal increase, which is associated with a ryanodine receptor (RYR) of skeletal muscles. In addition, the present invention can be used even after the onset of malignant hyperthermia and can inhibit an oxygen consumption rate abnormal increase even at concentrations lower than those of conventional agents for treating malignant hyperthermia, thereby enabling conventional agents for treating malignant hyperthermia to be replaced, and can be stably used, thereby being effectively usable in relevant industries. Furthermore, when using a skin regenerating composition, containing cADPR or NAADP antagonists, of the present invention, the skin can be protected from skin cell damage caused by UV-B of ultraviolet rays, and the skin regenerating composition has an excellent ability to recover and regenerate damaged skin and has no side effects on the same, thereby being usable in various forms such as a skin external preparation, a pharmaceutical composition, a cosmetic composition, and a food composition.

Dependencies are inferred from the claim text.